Dupilumab Linked to Increased Risk of Cutaneous T Cell Lymphoma in Atopic Dermatitis Patients: Study Dr Riya Dave23 April 2024 10:15 PM ISTResearchers have found that the use of dupilumab, a human monoclonal antibody targeting the IL-4 alpha receptor, is associated with an increased risk...
Dupilumab safe to continue during vaccine administration in children with AD reveals study Aditi20 March 2024 7:00 PM ISTDupilumab inhibits interleukin (IL)-4 and IL-13 signalling. This monoclonal antibody also acts as an immunomodulator. The current recommendation is to...
Dupilumab treatment may improve work productivity in patients with atopic dermatitis: Study Medha Baranwal19 March 2024 2:30 AM ISTJapan: A recent study published in Experimental Dermatology has shed light on the impact of 1-year treatment with dupilumab on work productivity in...
Tezepelumab novel therapeutic approach in uncontrolled severe non-type 2 asthma, case study suggests Medha Baranwal12 March 2024 3:00 AM ISTJapan: A recent case study published in Respirology Case Reports has shown that Tezepelumab could serve as a novel therapy for patients with...
Dupixent application accepted for priority review by USFDA for COPD with type 2 inflammation Ruchika Sharma23 Feb 2024 4:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Sanofi Dupixent gets Japenese nod for chronic spontaneous urticaria Ruchika Sharma18 Feb 2024 10:00 AM ISTParis: Sanofi has announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization...
Higher-exposure to dupilumab may effect weight gain among children with eosinophilic esophagitis Niveditha Subramani2 Feb 2024 1:45 AM ISTDupilumab is a popular drug commonly marketed as Dupixent. It was first approved by the FDA in 2017 and is currently used to treat atopic dermatitis,...
Sanofi Dupixent approved by USFDA for pediatric patients aged 1 to 11 years with eosinophilic esophagitis Ruchika Sharma28 Jan 2024 2:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of...
USFDA updates Sanofi Dupixent label for atopic dermatitis Ruchika Sharma18 Jan 2024 3:00 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent (dupilumab) in atopic dermatitis,...
Dupilumab effective for refractory asthma complicated by recurring chronic eosinophilic pneumonia Dr. Shravani Dali1 Jan 2024 8:15 AM ISTDupilumab promising treatment for refractory asthma complicated by recurring chronic eosinophilic pneumonia suggests a new study published in the...
Dupilumab therapy safe against Bullous Pemphigoid finds JAMA study Jacinthlyn Sylvia22 Nov 2023 4:30 PM ISTDupilumab, a potentially novel therapy for bullous pemphigoid (BP), has shown encouraging results in a retrospective cohort study conducted by the...
Dupilumab may rapidly improve sleep parameters among patients with chronic rhinosinusitis and nasal polyps Aditi30 Oct 2023 2:30 PM ISTChronic rhinosinusitis (CRS) is a prolonged inflammation of the sinus (nasal cavity and paranasal) and is classified into CRSwNP (CRS with nasal...
